Upload
others
View
20
Download
0
Embed Size (px)
Citation preview
KRISANI BIO SCIENCES PVT. LTD.
Flat – B2, 2nd Floor, Suryateja Apartments, Hindi Nagar,
Punjagutta, Hyderabad, Telangana – 500078.
Email: [email protected] . URL: www.Krisanibio.com
Contact Number: +91 98494 33333.
Overview:
Krisani Biosciences is pioneering in rapidly and cost effectively design, develop,
and commercialize best-in-class innovative therapies for the treatment of
Copper toxicity (Wilson’s disease), Non-Alcoholic Steatohepatitis (NASH),
Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington's disease
and Hepatic Disorders; which can provide multiple benefits to patients, caregivers,
and consumers. Using our proprietary technologies was able to deliver unique
therapeutic molecules with enhanced safety and efficacy. The resulting new
molecular entities (NME) provide competitive advantage through product and
technology driven multiple layers of intellectual property protection such as
patents, trademarks and know-how; in addition to mitigating risks in various
stages of development and lowering regulatory hurdles.
Business Model:
KrisaniBio is an innovative biopharmaceutical company with a value driven
sustainable business model with highly differentiated, potential best in class
therapeutics to treat significant and life-threatening diseases.
We are committed to developing therapeutic products that we elieve best- in-class
with the potential to be more effective and safer products than the current
standard of care or other products in development. Our strategic approach to
drug development builds on internally and externally generated knowledge to
identify and develop proprietary and highly differentiated products, as well as
enables the company to limit development risks and costs.
By applying our distinctive technologies and capabilities, and by utilizing an
expeditious approach where possible to minimize development risk and costs,
we believe that we can create substantial value while being very cost effective.
Krisani Biosciences is focused to rapidly and cost-effectively design, develop and
out-license or collaboratively develop products by strategic alliances or
partnerships. Design, protection of the associated intellectual property and
development work will be carried out in Krisani Biosciences Private Limited. After
successful completion and validation of early stage proof-of-concept studies,
Krisani Biosciences leverages its assets for strategic collaboration or partnering
with multinational pharmaceutical companies to further develop and recognize
value or out-license the clinical candidate and set royalties and milestones,
thereby meeting projected revenues.
By maintaining a lean infrastructure, and working collaboratively with others,
including leading academic researchers, clinical centers, contract research
organizations, and contract manufacturing organizations, we are able to efficiently
and cost effectively advance multiple programs in parallel. As the product
development programs at Krisanibio continues to advance and mature, the
company intends to establish strategic alliances and collaborations in certain
areas with leading pharmaceutical and medical device companies. The primary
objective of such partnerships is to accelerate product development efforts, and to
maximize stakeholder value.
Research and Development:
KrisaniBio's R&D has built one of the strongest and broadest pipelines of potential
new candidates. We believe the pipeline has the potential to deliver value to
patients and payers and improve rates of financial return on our R&D investment.
The primary goal of our R&D function is to appropriately progress our pipeline
products safely and efficiently to deliver innovative new medicines.
KrisaniBio’s has a portfolio of products in the pipeline. The company allocates its R&D
investment with reference to the potential returns available from its target
therapeutic markets and the technical and commercial aspects, those factors are
reviewed at each phase of the development process and are central in the
decision to proceed to the next stage. At the centre of this strategy, we will focus
our molecules R&D and investments in Neuroscience Pain (Market potential: $29.8
Billion); Neurodegenerative Disorders ($19 Billion); Hepatology-($9 billion) and
Cardiovascular Diseases ($116 Billion).
KrisaniBio's pipeline is rich in Preclinical and first in human entries aimed at
important unmet medical needs such as Copper toxicity, NASH, Neuropathic
Pain; Liver Cirrhosis; Hypertriglyceridemia; Oncology, Cystinosis and Huntington's
Disease. With biomedical science Advancing on all fronts, we are aiming to work
more collaboratively with global clinical research and development organizations
and other pharmaceutical and biotech companies in ways that allow us to share
risk and gain access to new knowledge and technologies.
Intellectual Property
It is our policy to try to obtain patents on commercially important, protectable
inventions discovered or developed through our R&D activities. Patent
protection for new active ingredients is available in major markets and patents
can also be obtained for new drug formulations, manufacturing processes, medical
uses and devices for administering products.
Krisani Biosciences applies its proprietary drug discovery platform to identify
novel product candidates in a number of disease areas, including Wilson's
disease, NASH, Cardiovascular Diseases, Neuropathic Pain and
Neurodegenerative diseases. By applying our proprietary design platform, we
have discovered and advanced into pre-clinical trials a portfolio of three product
candidates targeting multiple diseases. To-date, the company is currently
working on 5 therapeutic areas and had granted 12 international and national
patents.
To-date, the company has filed one patent application on the novel diagnostic
technology and its applications in multiple disease areas with the United States
Patent and Trademark Office (USPTO) and Indian Patent Office (IPO).
Application Number Title Patent No. / Status
US20120022147 2,6 Xylidine Derivatives for the treatment of Pain US8283375B2
GRANTED
US20130225680A1 Compound, Composition and uses thereof for the
treatment of Hypertriglyceridemia US844570713B1
GRANTED
US20140221476A1 Compound, Composition and uses Thereof(Cystinosis) US8871805B2
GRANTED
2012-555510 Compound, Compositions, Formulations and their uses
thereof Granted,
Japan
221686 Compound, Compositions, Formulations and their uses
thereof Granted,
Israel
2011-222649 Compound, Compositions, Formulations and their uses in
the treatment diseases related to copper retention or Hepatic Disorders
Granted, Australia
11731488 Compound, Compositions, Formulations and their uses
thereof Granted,
European PO
2013-513777 Cysteamine Derivatives and their use in the treatment of NASH (FR) derives Cysteamine ET LEUS utilisation DANS
LE treatment DESTEATOPATHIES NON ALCOOLIQUES
Granted, Japan
2011-263423 Cysteamine Derivatives and their use in the treatment of
NASH Granted, Australia
2580204 Cysteamine Derivatives and their use in the treatment of NASH (FR) derives Cysteamine ET LEUS utilisation DANS
LE treatment DESTEATOPATHIES NON ALCOOLIQUES
Granted, European PO
223241 Cysteamine Derivatives and their use in the treatment of
NASH Granted,
Israel
201303972-2 Method and System for Prognosis and Treatment of
Diseases using Portfolio of Genes Granted,
Singapore
Pipeline Profile:
KB-HD-01: Wilson’s disease:
A novel prodrug and a novel Copper metal chelator with Significant Superior
Pharmaceutical Profile compared to the marketed drugs. Potent Copper Chelator
cum Antioxidant Lead and has better Drug Profile than D-Penicillamine with
Neuroprotective Properties. Presently chemical synthesis completed and pre-
clinical data is encouraging towards proof of concept studies.
KB-GE-001:Non-Alcoholic Steatohepatitis (NASH):
A novel Co- drug for liver cirosis and exhibits multiple fold activity than the marketed
drugs. Chemical synthesis completed and preclinical work under progress
KB-CN-01: Neuropathic Pain:
A novel prodrug of a local anesthetic that alters signal conduction in neurons by
blocking the fast voltage gated sodium (Na+) channels in the neuronal cell
membrane; Longer duration of action with enhanced pharma cokinetics, safety
and efficacy; Enhanced neural blood flow, conduction and glucose transport.
Currently in the advanced Pre-clinical stage. The product portfolio has the potential
for the treatment of Diabetic Neuropathy, Post-Herpetic neuralgia, Chronic Pain,
Spinal Cord Injury and Peripheral Neuropathy. A US Patent has been granted
US8283375B2 in the Month of October 2012.
KB-CV-001: Hypertriglyceridemia:
A novel new molecular entity (NME) of Eicosapentaenoic acid. KB-CV-001 is an
ULTRA-PURE form of EPA (Eicosapentaenoic acid) in an ESTER form and when
compared to the US-FDA recently approved entity, Amarin Plc’sEPA ester
(VASCEPA) product which claims to have above 96% pure EPA Ester only, whereas,
KB-CV-001 EPA analytical purity was found to be 99% and has a greater potential.
KB-CV-001is also a derivative of an endogenous compound, 2-aminoethanethiol
and is a Chemically Highly Stable compound.
KB-ND-01: Huntington’s disease (Orphan category):
A novel prodrug of Potent Trans glutamase inhibitor, Neuroprotection by
increasing brain derived neurotrophic factor (BDNF) levels, Long duration of action
with enhanced pharmacokinetics, tolerability, safety and efficacy, Potential to
penetrate through Blood-Brain Barrier and stabilizes the neural membrane.
Currently in the advanced Pre-clinical stage. The product portfolio has also the
potential for the treatment of Nephropathic Cystinosis, Hypertriglyceridemia and
Non- alcoholic Steatohepatitis (NASH).
Creating a successful and sustainable business is
about more than financial results. We place
great importance not just on what we achieve but
on how we achieve it. Running a responsible,
values-based business is embedded in our
strategy.